Table 2 Comparison of characteristics between OPN-156del/del and -156G genotype groups
Variable | del/del (n=190) | G/del+G/G (n=128) | P-value |
|---|---|---|---|
Gender (male/female) | 114/76 | 75/53 | 0.816 |
Age (years) | 63.1±9.3 | 62.7±9.4 | 0.712 |
BMI (kg m−2) | 24.0±3.6 | 24.1±3.4 | 0.853 |
Systolic blood pressure (mm Hg) | 158.7±26.6 | 156.7±30.2 | 0.606 |
Diastolic blood pressure (mm Hg) | 93.2±16.4 | 92.6±17.5 | 0.771 |
Antihypertensive drug treatment | 91 (48.1%) | 66 (51.6%) | 0.569 |
Calcium channel blockers | 62 (32.8%) | 43 (33.6%) | 0.904 |
ACE inhibitors and/or ARBs | 52 (27.5%) | 38 (29.7%) | 0.704 |
ACE inhibitors | 30 (15.9%) | 17 (13.3%) | 0.629 |
ARBs | 27 (14.3%) | 23 (18.0%) | 0.433 |
β-Blockers | 17 (9.0%) | 15 (11.7%) | 0.452 |
α-Blockers | 6 (3.2%) | 2 (1.6%) | 0.481 |
Diuretics | 17 (9.0%) | 11 (8.7%) | 1.000 |
Diabetes | 50 (26.3%) | 45 (35.2%) | 0.105 |
HbA1c (%) | 5.8±1.4 | 6.1±1.5 | 0.110 |
Fasting blood glucose (mg dl−1) | 112.7±47.6 | 115.5±35.5 | 0.591 |
Hyperlipidemia | 102 (53.7%) | 65 (50.8%) | 0.648 |
Total cholesterol (mg dl−1) | 206.6±37.1 | 203.4±36.3 | 0.464 |
Triglyceride (mg dl−1) | 144.1±87.1 | 147.9±92.9 | 0.716 |
HDL (mg dl−1) | 54.2±16.8 | 52.7±13.7 | 0.466 |
Diabetes-related treatment | 37 (19.8%) | 34 (26.8%) | 0.170 |
Lipid-lowering treatment | 37 (19.6%) | 32 (25.0%) | 0.269 |
Coronary heart disease | 18 (9.5%) | 18 (14.1%) | 0.212 |
